Analyzing the Cost Implications of Healthcare Policies

As a practicing surgeon, the proposed federal reductions to Medicaid and Medicare will significantly affect my surgical patients. These cuts could compromise the quality of care and patient outcomes, especially within underserved populations. Understanding the potential consequences of these decisions is important to build future expectations. Patient & Post-Op Care Impacts: Many low-income, elderly, or disabled patients rely on Medicaid for crucial home and community-based services (HCBS) after surgery. Federal cuts may force states to reduce or eliminate these "optional" HCBS, pushing patients into less appropriate institutional care (Nursing homes) or leaving them without essential home support. This raises complication and readmission risks, impacting surgical outcomes. Cuts also will increase number of uninsured patients who are less likely to access vital home health services. This significantly increases their risk of complications, infections, and reoperations, compromising long-term surgical success. Furthermore, existing health disparities for underserved populations will worsen, leading to delayed care, neglected post-operative needs, and poorer outcomes. Hospital's Impacts: Underserved hospitals, where many of my patients receive care, face severe financial strain from federal payment cuts. This revenue loss forces them to absorb higher uncompensated care costs when uninsured patients seek emergency care, shrinking operating margins. With less financial stability, hospitals are less likely to invest in home-based post-operative care infrastructure—technology, training, and resources. This directly affects my confidence in discharging patients to receive outpatient follow-up, which will increase hospital length of stay and further hospital losses. Medicaid cuts exacerbate home healthcare workforce shortages. Inadequate reimbursement makes it hard to recruit and retain skilled talents for crucial post-surgical home visits, meaning my patients may miss timely wound care, medication management, or physical therapy, jeopardizing recovery. The lack of home care will increase preventable complications and poor follow-up, significantly increasing hospital readmission rates. This not only burdens the system but also signals a failure in postoperative care continuity, reflecting poorly on patient outcomes. Societal & Economic Impacts: When professional home care is unavailable, the burden falls disproportionately on unpaid family caregivers, leading to burnout, financial strain, and workforce exits, with broader societal repercussions. In essence, federal funding cuts create a "domino effect": they destabilize hospitals, cripple home healthcare, and ultimately limit my patients' access to vital post-surgical support. This translates directly to poorer surgical outcomes, increased patient suffering, and higher long-term healthcare costs. As a surgeon, it is concerning that external factors directly hinder the success of the care I provide.

A Cost–Benefit Analysis (CBA) in health insurance is the systematic process of comparing the costs of providing health insurance (or implementing a health insurance scheme) with the benefits it generates for individuals, insurers, and society. It helps policymakers, insurers, and stakeholders determine whether an insurance product or reform is worthwhile. Here’s a breakdown: 1. Costs in Insurance 📌Underwriting, claims management, marketing, IT systems, and regulatory compliance. 📌Reimbursements to hospitals, doctors, and other health providers. 📌Inefficiencies caused by moral hazard (excessive use of care) and adverse selection (high-risk individuals joining disproportionately). 2. Benefits of health Insurance 💡 Shielding individuals from catastrophic health expenditures or large losses. 💡Insured populations are more likely to seek timely care. 💡Spreading risks across many people lowers individual exposure. 💡Healthier populations are more productive economically. 💡Social health insurance can reduce inequalities in healthcare access. 3. Approaches to CBA in health Insurance ➡️ Assigning monetary values to both costs and benefits. Example: calculating the net present value (NPV) of a new health insurance scheme. ➡️ Considering non-monetary benefits like fairness, health system strengthening, and social stability. ➡️ Unlike cost-effectiveness (which focuses on outcomes per unit cost, e.g., cost per QALY gained), CBA tries to express all outcomes in monetary terms. 4. Applications in Health Insurance 🔄Deciding whether to introduce coverage for new services (like preventive care). 🔄 Evaluating reforms: e.g., Kenya’s Social Health Insurance Fund (SHIF) – balancing collection of premiums, government subsidies, and benefits to households. 🔄Assessing whether subsidizing premiums for the poor yields greater long-term social and economic returns than direct cash transfers. 5. Key Metrics 1️⃣ Net Present Value (NPV): NPV=Total Benefits – Total Costs 2️⃣ Benefit-Cost Ratio (BCR): BCR=Total Benefits/Total Costs. A ratio >1 indicates the insurance scheme is worthwhile. 3️⃣ Internal Rate of Return (IRR): discount rate at which NPV = 0, useful for long-term schemes. 6. Example in health Insurance: ✔️ Costs: $200 million in subsidies + $50 million in admin costs annually. ✔️ Benefits: $400 million in avoided catastrophic health expenditures, $100 million in productivity gains, and $50 million in long-term savings from preventive care. ✔️ Result: Benefits = $550 million; Costs = $250 million → BCR = 2.2 (economically justified).

New modelling shows that government will need to deliver on NHS productivity and prevention promises to prevent health costs spiralling. Joint analysis by LCP and IPPR projects the cost of government-funded healthcare to 2034/35 under various scenarios. If recent trends continue, healthcare spending will grow to over 9.5% of GDP in 2034/35. However, improvements in productivity and prevention could almost completely flatten this growth, with spending remaining at around 8% of GDP in a decade’s time. If delivered, these improvements would provide annual savings of over £50bn in 2034/35, comparable to the current UK defence budget. Excellent work from Andrew Pijper and Dr Godspower Oboli updating previous LCP Health Analytics modelling to reflect the latest data and developments, and new scenarios developed with IPPR for their new report. It was a pleasure to collaborate with Annie Williamson, lead author of the insightful new report "Realising the reform dividend: a toolkit to transform the NHS", which is out today. Links in comments to LCP blog and analysis and the IPPR report.

Rising insurance premiums should not be explained by medical loss ratio alone. MLR is useful, but it is only one indicator. A more credible assessment should also consider claims cost per insured life, case mix, provider price growth, utilisation growth, administrative expense ratio, underwriting margin, capital adequacy, and the out-of-pocket burden shifted to patients. To tackle rising insurance premiums, I find it helpful to use a simple 5-part framework: 1. Measure properly Look beyond a single ratio. Separate price growth from utilisation growth, and distinguish real medical inflation from administrative inefficiency or margin expansion. 2. Moderate demand intelligently Use co-payments, deductibles, and benefit design carefully to reduce low-value care, without deterring necessary care. 3. Manage provider incentives Strengthen fee benchmarks, episode-based payment where appropriate, panel governance, and pre-authorisation for selected high-cost services. 4. Monitor insurer behaviour Require greater transparency on expenses, margins, claims denial patterns, and service performance, not just claims payouts. 5. Minimise patient harm Any premium control strategy should protect affordability, access, and continuity of care, especially for patients with genuine healthcare needs. This matters because the same premium increase can mean very different things. It may reflect genuine medical inflation and more appropriate care. But it may also reflect higher operating costs, preserved margins, weak cost control, or greater transfer of financial risk to patients. In healthcare finance, the real issue is not whether spending rises. It is whether the increase is proportionate, transparent, and tied to real value. As Program Coordinator for the Master of Health Management and Policy at Newcastle Australia Institute of Higher Education, I am interested in these questions because they sit at the intersection of policy, economics, regulation, and clinical reality. If you are interested in health insurance, healthcare finance, and the design of sustainable health systems, connect with me. Newcastle Australia Institute of Higher Education https://lnkd.in/gtHAXi8m

Singapore’s upcoming parliamentary debate on Integrated Shield Plan (IP) rider changes goes to the heart of a difficult but necessary trade-off in healthcare financing. On one hand, rising premiums and private healthcare costs are clearly unsustainable. Insurance designs that eliminate almost all out-of-pocket expenses weaken price signals and encourage higher utilisation. This is not about bad faith by patients. It is about incentives. When the marginal cost of care approaches zero, claims rise, premiums follow, and affordability for the wider risk pool steadily erodes. On the other hand, MPs are right to ask how families will cope if deductibles and co-payments become unaffordable at moments of medical stress. Sustainability cannot come at the expense of dignity or access. Cost sharing may be economically sound, but if poorly calibrated, it risks discouraging timely care, worsening health outcomes, or imposing sudden cash-flow shocks on households least able to absorb them. This debate is often framed as a matter of individual consumer choice. In reality, it produces systemic effects. Highly comprehensive riders may feel rational for one household, but collectively they drive higher utilisation, push up costs across the system, and increase pressure on public healthcare resources. The policy question is therefore not whether cost sharing should exist, but how much risk should be socialised, how much should remain visible, and how those boundaries are enforced fairly. Affordability must also be understood more broadly than premiums alone. It includes whether families can manage sudden deductibles, whether sufficient buffers and safety nets exist, and whether support mechanisms are well targeted rather than blunt. Cost sharing works only when paired with safeguards that recognise uneven financial resilience across households. At its core, this debate is a reminder that healthcare financing is a shared responsibility. Patients, insurers, providers, and policymakers all shape outcomes through incentives and expectations. Parliament’s discussion is therefore not just about insurance riders, but about fairness, resilience, and how we design systems that remain compassionate, credible, and sustainable over the long term. What do you think?

our peer-reviewed study on Medicaid losses out today: https://lnkd.in/gsctAMfv Based on empirically derived parameters from prior studies of health outcomes, healthcare systems, and local economies, the estimated health and economic impacts (per 100,000 people losing Medicaid coverage) include: 13-14 excess deaths annually 810-924 preventable hospitalizations annually ~2,582 jobs lost annually ~$1.2 billion in reduced economic output annually Rural hospitals face heightened risk of closure, with impact disproportionate to coverage losses due to the high concentration of patients on Medicaid in rural areas. Federally qualified health centers (FQHCs) experience revenue reductions of 18.7-26.1%.

As policymakers advance Medicaid work requirements—which mandate at least 80 hours/month of work, volunteering, or job training for able-bodied adults to maintain eligibility—the fallout for health systems could be substantial. Per a recent analysis from The New York Times, the 2025 Reconciliation Bill wouldn’t just require millions of Americans to verify employment status; it would also require states to build complex new eligibility-tracking systems with little lead time. 🔍  Why this matters for health systems: 1. Gaps in enrollment will grow, and systems will bear the cost: Millions of patients who are eligible for Medicaid may still lose coverage due to the complexity of new verification requirements. Many won’t complete the paperwork or meet digital access needs in time. Health systems will need to proactively screen and enroll these patients, or risk absorbing the cost of care. 2. Chronic care disruptions = more acute events: Coverage gaps interrupt regular care—diabetes screenings, cancer prevention, behavioral health check-ins—which can quickly escalate to costly ED visits and hospitalizations. 3. Early rollouts have shown real harm: In Arkansas, over 18,000 people lost coverage within months of work requirements taking effect in 2018. In Georgia, a similar policy launched in 2023 covers just 2,300 people, despite 90,000 being eligible, drastically reducing access and reimbursement for providers. 4. Disproportionate impact on vulnerable populations: Caregivers, people with fluctuating work hours, those without reliable internet, and marginalized communities are most likely to fall through the cracks. This drives deeper health inequities and higher downstream costs. 💡  What health systems should do now: ▪️ Prepare for a surge in uncompensated care, especially in rural and safety-net settings. ▪️ Implement proactive digital communication strategies to stay connected with at-risk patients between visits. ▪️ Invest in financial navigation and digital screening tools to help patients check and maintain eligibility across Medicaid, ACA plans, charity care, and other programs. ▪️ Monitor real-world outcomes in other states to inform outreach, capacity planning, and policy response. If you are a provider leader concerned about the pending changes, please reach out - happy to share the work we have done to model anticipated impacts and necessary changes.

As we begin the transition between administrations, we find ourselves in a sort of limbo, not unlike the shoulder season in a mountain town.  It’s time to brace ourselves for the uncertainty ahead. A prime example of this uncertainty emerged last week when the Biden administration proposed extending Medicare and Medicaid coverage to weight loss medications like Wegovy and Zepbound. If finalized, this decision would significantly expand access to GLP-1s for millions of Americans and clearly, effectively recognize obesity as a condition requiring medical treatment.  This move could have far-reaching implications for commercial health insurance plans. The proposal’s impact Under the new policy, an estimated 3.4 million Medicare beneficiaries and 4 million Medicaid enrollees would become eligible for obesity medications, at an estimated federal cost of $36 billion over 10 years. With bipartisan support and public interest growing—61% of Americans support Medicare coverage for obesity drugs—this policy could mark a turning point in how obesity is treated in the U.S. The evidence is clear that GLP-1s improve overall health, not just by aiding weight loss but by reducing the severity of obesity-related conditions, but critics are right to be concerned about high costs. A new reality for commercial plans If Medicare and Medicaid expand their coverage, commercial health plans will face heightened pressure to follow suit. It’s soon becoming table stakes to stay competitive in attracting and retaining members. Commercial plans still on the fence about covering obesity care may want to consider the following: Comprehensive Care Models: Just as CMS highlights the importance of using GLP-1s alongside broader obesity management strategies, commercial plans can partner with a solution like Vida that integrates nutrition counseling, mental health, and preventive care to maximize outcomes and mitigate costs. Workforce Implications: Employers are increasingly focused on workforce safety, retention, and productivity. Providing coverage for obesity care could be a way to meet those goals. Expanding Indications: These medications aren’t going away. In fact, the FDA may soon approve them for sleep apnea, kidney disease, fatty liver, and more. It’s better to get a strategy in place now for effective wraparound care and cost management. A catalyst for change For commercial health plans, the expansion of government coverage could be a catalyst for change. As one CMS leader noted, “The more friction there is in the system…the harder it is for people to get the care they need.” Removing those barriers may be the key to ensuring equitable care across all populations. I’m curious: how is your organization responding to the rising demand for GLP-1s?